Biotech Stocks See Major Selling Pressure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
UPDATE: BMO Capital Upgrades Biogen (BIIB) to Outperform
March 6, 2014 6:38 AM EST(Updated - March 6, 2014 12:10 PM EST)
BMO Capital upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $422. Analyst Jim Birchenough, M.D. sees too many transformational opportunities to ignore.
The firm conducted an extensive pipeline review, and updated their financial model to reflect nearer-term opportunities for new product growth with ELOCTATE and... More
